drugset / Trial / NCT03531242

Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults

NCT03531242 ↗

Phase 2 Not yet recruiting 500 enrolled U.S. Army Medical Research and Development Command
Non-randomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the safety and immunogenicity of VEE vaccine, C-84, TSI-GSD 205, Lot 7, Run 1, and collect data on the incidence of occupational VEE infection in vaccinated personnel.

Timeline

Start
2021-06
Primary completion
2023-12
Completion
2024-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject C-84 Vaccine 0.5 ml Subcutaneous